Us Congress 2025-2026 Regular Session

Us Congress House Bill HB1798

Introduced
3/3/25  

Caption

End Tobacco Loopholes Act

Impact

Should HB1798 be enacted, it would lead to substantial changes in the taxation landscape for tobacco products. For example, the proposed tax rates for small cigars would rise to $100.66 per thousand while large cigars would face a new taxation rate of $211.38. Similarly, smokeless tobacco and roll-your-own tobacco would see their effective rates nearly doubled. The introduction of taxes on nicotine, particularly for its use in vaping products, could redefine how these items are regulated and taxed, thus impacting manufacturers and consumers alike.

Summary

House Bill 1798, known as the 'End Tobacco Loopholes Act', aims to amend the Internal Revenue Code of 1986 by establishing tax rate parity across all tobacco products. The bill proposes significant increases in excise taxes for various items including cigarettes, smokeless tobacco, and roll-your-own tobacco, along with imposing new taxes on nicotine as a substance. This comprehensive initiative seeks to elevate tax levels uniformly, thereby closing gaps in current taxation practices that many view as inequitable among different tobacco products.

Contention

The bill is likely to face scrutiny from various stakeholders including tobacco manufacturers, public health advocates, and financial analysts. Supporters argue that the increased taxes could reduce tobacco consumption, thereby improving public health outcomes and generating additional revenue for health programs. However, opponents may contend that such a tax increase could disproportionately affect low-income individuals and lead to an increase in illicit trade of tobacco products, raising concerns about enforcement and compliance.

Congress_id

119-HR-1798

Introduced_date

2025-03-03

Companion Bills

US SB819

Related End Tobacco Loopholes Act

Similar Bills

US SB1956

Invent Here, Make Here Act of 2024

US HB8074

Forever Chemical Regulation and Accountability Act of 2024

US SB1040

Drug Competition Enhancement Act

US HB10238

Medical Innovation Act of 2024

US SB5339

Medical Innovation Act of 2024

US HB7744

Infant Formula Made in America Act of 2024

US SB5459

A bill to amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.

US SB5638

A bill to secure the supply of drugs in the United States, and for other purposes.